Should you buy Corbus Pharmaceuticals stock now?
Yes, the technical signal for Corbus Pharmaceuticals is currently BUY. Corbus Pharmaceuticals trades at $0.00 as of 8/28/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.490 with rising momentum (signal: 0.365); RSI is at 66.8 (neutral zone). This is a technical observation based on current data, not investment advice.
What is the price target for Corbus Pharmaceuticals stock?
There is currently no active analyst price target for Corbus Pharmaceuticals.
Is Corbus Pharmaceuticals a dividend stock?
No, Corbus Pharmaceuticals does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Corbus Pharmaceuticals stock?
Corbus Pharmaceuticals is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 79.3%, which classifies the stock as Extremely speculative.
Is Corbus Pharmaceuticals overvalued?
Corbus Pharmaceuticals has the following valuation ratios: a P/S ratio of 169.9, a P/B ratio of 2.1.
Is Corbus Pharmaceuticals overbought?
No, Corbus Pharmaceuticals is not overbought. RSI is at 66.8 (neutral zone). The technical indicators show: RSI is at 66.8 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, MACD is positive with rising momentum (bullish).
When is the next Corbus Pharmaceuticals earnings report?
The date of the next earnings report for Corbus Pharmaceuticals has not been published yet. Check the company's investor calendar for updates.
Is Corbus Pharmaceuticals shorted?
Yes, Corbus Pharmaceuticals is shorted with 12.7% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Corbus Pharmaceuticals stock?
No, insiders are not buying Corbus Pharmaceuticals shares – they are net sellers. Over the last 3 months, insiders have made 3 purchases and 5 sales. On a net basis, 239,150 $ worth of shares were sold. Across the last 20 reported transactions, the split is 3 purchases and 17 sales, with a net 1,587,956 $ sold. Active sellers include Moran Sean F., Cohen Yuval, Kung Winston and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Corbus Pharmaceuticals a good stock?
Based on our total score, Corbus Pharmaceuticals is rated as a disastrous stock with a total score of 16 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 16/100, Quality: 6/100, Momentum: 26/100. In addition: technical signal: Buy. Whether Corbus Pharmaceuticals is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Corbus Pharmaceuticals stock?
The outlook for Corbus Pharmaceuticals based on current data: Detailed data is currently not available. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Corbus Pharmaceuticals stock moving?
Corbus Pharmaceuticals is moving right now. The technical indicators show: MACD is positive with rising momentum (bullish signal); short interest is 12.7% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Corbus Pharmaceuticals go?
There is currently no active analyst price target for Corbus Pharmaceuticals. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Corbus Pharmaceuticals fall?
We lack enough history to give a specific floor for Corbus Pharmaceuticals. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Corbus Pharmaceuticals do?
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of... The company belongs to the Healthcare sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Corbus Pharmaceuticals as an investment.
Did Corbus Pharmaceuticals raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Corbus Pharmaceuticals. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Corbus Pharmaceuticals making money or losing money?
We have no current profitability data for Corbus Pharmaceuticals. See the latest report in the earnings history above.
Can Corbus Pharmaceuticals go bankrupt?
The bankruptcy risk of Corbus Pharmaceuticals is rated as elevated. Altman Z2 (a model for assessing financial distress) is -11.57 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 1 — which is weak. Debt relative to equity is 9% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Corbus Pharmaceuticals have a lot of debt?
No, Corbus Pharmaceuticals has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 9%. For the healthcare sector, anything below 80% counts as low debt. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.